Table 2 Summary of study characteristics for each antimalarial drug
| Â | Quinine (51 studies) | Mefloquine (45 studies) | Lumefantrine (39 studies) | Piperaquine (24 studies) | Halofantrine (22 studies) | Chloroquine (17 studies) | SP (14 studies) | Amodiaquine (10 studies) | Primaquine (7 studies) |
|---|---|---|---|---|---|---|---|---|---|
Range of dates studies were published | 1982–2014 | 1983–2012 | 1997–2014 | 2003–2016 | 1993–2004 | 1983–2014 | 1983–2015 | 1987–2014 | 1992–2015 |
Countries where studies were most frequently conducted in (% of studies) | Thailand (43%) Vietnam (8%) Myanmar (8%) | Thailand (54%) Brazil (11%) | Thailand (23%) Kenya (13%) | Thailand (25%) Cambodia (17%) | France (32%) Nigeria (18%) | Thailand (41%) India (24%) | Brazil (36%) Thailand (21%) | No majority (each trial in different country) | Thailand (71%) |
Median (range) number of participants | 59 (7–561) | 94 (8–3673) | 165 (12–1553) | 130 (12–10,925) | 38.5 (8–120) | 58 (11–456) | 99 (20–3673) | 32 (10–336) | 16 (8–329) |
% (number) of studies OLRCT | 43 (22) | 56 (25) | 36 (14) | 54 (13) | 18 (4) | 18 (3) | 50 (7) | 40 (4) | 14 (1) |
% (number) of studies DBRCT | 6 (3) | 24 (11) | 18 (7) | 8 (2) | 9 (2) | 35 (6) | 36 (5) | 0 (0) | 14 (1) |
% (number) of studies OLRCTX | 0 (0) | 2 (1) | 10 (4) | 8 (2) | 14 (3) | 6 (1) | 0 (0) | 40 (4) | 57 (4) |
% (number) of studies non-comparative | 29 (15) | 9 (5) | 21 (8) | 13 (3) | 45 (10) | 6 (1) | 0 (0) | 10 (1) | 14 (1) |
% (number) of studies primary outcome CV safety | 20 (10) | 13 (6) | 13 (5) | 13 (3) | 41 (9) | 18 (3) | 14 (2) | 20 (2) | 0 (0) |
% (number) of trials PK or PK/PD primary aim | 26 (13) | 24 (11) | 26 (10) | 21 (5) | 27 (6) | 53 (9) | 7 (1) | 60 (6) | 71 (5) |
% (number) of papers PK/PD primary aim | 6 (3) | 9 (4) | 10 (4) | 4 (1) | 13 (3) | 18 (3) | 0 (0) | 10 (1) | 0 (0) |